Lilly is deploying what it describes as the largest and most powerful Artificial Intelligence factory wholly owned and operated by a pharmaceutical company. The deployment centers on drug discovery and is built around the world’s first Nvidia DGX SuperPOD configured with DGX B300 systems. The company identifies the platform as Blackwell-based, positioning it at the leading edge of accelerated computing for research workflows.
By assembling a DGX SuperPOD with DGX B300 systems, Lilly signals an intent to concentrate substantial compute capacity behind its discovery efforts. The Blackwell-based infrastructure is presented as a foundation for applying Artificial Intelligence at scale in pharmaceutical research. While specific performance figures are not detailed, the description emphasizes magnitude and first-of-its-kind status within the sector, underscoring a focus on high-end training and inference environments typically associated with large-model experimentation and analysis in drug discovery.
The company frames the installation as an Artificial Intelligence factory to support discovery programs, highlighting ownership and operation within the organization rather than relying on shared external resources. The combination of a Nvidia DGX SuperPOD and DGX B300 systems indicates a cohesive, production-grade stack intended to support sustained workloads. With the platform characterized as Blackwell-based and dedicated to drug discovery, the move reflects a push to integrate advanced accelerated computing into the core of pharmaceutical research operations.
